Enliven Therapeutics, Inc.
Every calculator, already run for ELVN
Open the full toolkit →You have the numbers on ELVN. Get the argument.
A written report on which of these readings actually decide the outcome for Enliven Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering ELVNAnalyst Price Target Disagreement for Enliven Therapeutics, Inc.
Wall Street's bull case implies +73% from the current price; the bear case implies +46%. Analysts are relatively aligned on ELVN's range.
Ownership & short interest
Insider Trading Activity for ELVN
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is based in Burlingame, California.
ELVN — frequently asked
Is ELVN a buy right now?
Wall Street's consensus rating on Enliven Therapeutics, Inc. is Strong Buy across 14 analysts, with a mean price target of $74.33 (+57% vs. the current $47.36). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Enliven Therapeutics, Inc.?
Analysts covering Enliven Therapeutics, Inc. (ELVN) range from a bear-case target of $69.00 to a bull-case high of $82.00, with a mean consensus target of $74.33 across 12 analysts. The spread of $13.00 (27% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Enliven Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Enliven Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ELVN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Enliven Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.